Regeneron (RGEN) is a leading biotechnology company; its science-driven approach has resulted in eight FDA-approved drugs and more than 20 product candidates in clinical development, explains Ingrid Hendershot, a lvalue-focused money manager and editor of Hendershot Investments.
Sales of Regeneron’s lead drug, EYLEA, approved to treat age-related macular degeneration and diabetic edema, have grown at double-digit rates for seven years without a single price increase. In 2019, EYLEA generated net product sales in the U.S. of $4.6 billion.
Global sales of Dupixent, a first-in-class treatment option for several Type 2 inflammatory diseases, jumped 151% to $2.3 billion in 2019 with numerous new indications for the drug on the horizon.
In 2019, the firm’s PD-1 inhibitor Libtayo, launched just a year earlier, became the standard of care for advanced cutaneous squamous cell carcinoma, generating global net product sales of $194 million.
Its COVID-19 antibody drug was authorized on Nov. 22 by the FDA to treat patients 12 years of age and older—including people over 65, who are not hospitalized but are at high risk of the disease increasing in severity.
MoneyShow’s Top 100 Stocks for 2021
The top performing newsletter advisors and analyst are back, and they just released their best stock ideas for 2021. Get your FREE copy of MoneyShow’s 2021 Top Picks report here and see why the nation's leading investment experts believe these stocks will significantly outperform the market in 2021.
Regeneron generated healthy growth during the past five years with revenues compounding at an 18% annual rate as net income and EPS grew at a high 35% annual pace.
The company routinely reinvests 30% of revenues in R&D, compared to the industry average of about 20%. Its profitable operations consistently deliver double-digit net profit margins and returns on shareholder equity exceeding 20%.
Long-term investors seeking a profitable prescription should consider Regeneron, a high-quality innovator with profitable growth and a healthy balance sheet with nearly $6 billion in cash and marketable securities.
